drug make immuno-oncolog easier
swallow initi outperform
aptli name forti seven inc focus could hottest
target immuno-oncolog sinc substanti bodi clinic data hand
forti seven emerg clear leader among pack compani pursu
immun checkpoint rel convent checkpoint like
regul entir differ set immun cell provid new
opportun therapeut intervent indic exist drug fall short
forti seven lead product demonstr impress safeti efficaci
monotherapi combin antibodi multitud clinic
readout expect next month initi coverag outperform
rate pt
inher tricki target wide express healthi
tissu cancer cell alik howev forti seven devis eleg
solut design dose strategi lead therapeut antibodi
strike near-perfect balanc safeti
fundament challeng biolog
first antibodi enter trial compani
built industry-lead safeti efficaci databas
patient treat ahead forti seven ipo subject two high-
profil oral present meet includ monotherapi
data mix tumor combin therapi data non-hodgkin lymphoma
monotherapi demonstr object respons tough-to-
treat indic includ heavili pretreat ovarian cancer dlbcl
aggress form nhl howev believ mechanist best suit
combin drug shown synergi t-cell checkpoint inhibitor
tumor-target therapi rituximab
view compani compel clinic data dlbcl phase
trial combin rituximab elicit complet respons rate
heavili pretreat patient believ point clear benefit soc
could repres palat altern autolog car-t therapi
scope forti seven clinic develop program set apart
closest competitor ipo classmat mani remain preclin
expect see steadi stream new data compani six
on-going clinic trial could de-risk lead program establish
proof-of-concept indic aml colorect bladder cancer
forti seven inc biotechnolog
compani focus develop novel
har
power innat immun system
analyst certif import disclosur see disclosur
success clinic develop dlbcl ovarian
us eu commerci combin
rituximab
non-risk-adjust sale dlbcl
us eu commerci combin
avelumab
non-risk-adjust sale pt-resist ovarian
success commerci addit indic
earlier anticip regulatori approv dlbcl
base acceler approv pathway
earlier anticip regulatori approv ovarian
influx non-dilut fund new research collabor
licens agreement partnership
believ could find util wide rang
cancer forti seven pioneer biolog
believ compani lead product hold lead
clinical-stag competitor valuat center
commerci potenti r/r dlbcl ovarian cancer
dlbcl could provid viabl altern car-t
therapi drug shown highli encourag sign
activ pt-resist ovarian cancer patient pair
mainstay compon combin regimen solid
updat phase data monotherapi ovarian cancer
updat phase data nhl w/rituximab
updat phase trial w/cetuximab
initi safeti efficaci data phase trial ovarian
initi phase result aml w/atezolizumab
initi phase result bladder cancer w/atezolizumab
initi phase result aml/md w/azacitidin
failur delay clinic develop dlbcl and/
ovarian cancer
lower anticip market penetr dlbcl
unfavor price reimburs payer
price target base risk-adjust sum-of-th part npv contribut combin therapi
dlbcl ovarian cancer includ forti seven project cash per share arriv price target
risk includ price clinic regulatori financ market competit trade volatil
forti seven inc clinical-stag biotechnolog compani base menlo park
ca compani develop therapi har immun system
fight cancer forti seven lead asset monoclon antibodi
inhibit checkpoint innat immun system block
macrophage-medi tumor clearanc discov compani
scientif founder stanford univers forti seven pursu ambiti
clinic develop program includ six on-going trial across rang
solid liquid tumor indic activ trial includ phase trial
investig monotherapi multipl cancer type two phase trial
acut myeloid leukemia aml phase trial rituximab non-hodgkin
lymphoma nhl phase trial cetuximab colorect cancer
phase trial avelumab ovarian cancer forti seven ovarian
cancer program support merck kgaa clinic trial
collabor suppli agreement separ clinic trial collabor
genentech conduct two trial combin atezolizumab
bladder cancer aml compani complet initi public offer
june rais gross proce approxim
initi coverag forti seven outperform rate price
target next month see one promis
new checkpoint target immuno-oncolog sinc believ forti
seven emerg clear leader field compani accumul
clinic experi competitor drug
shown clear anti-tumor activ cancer patient believ least
year ahead closest competitor proprietari dose strategi hand
believ strike excel balanc safeti efficaci
could find therapeut util rang cancer
forti seven made splash meet initi result
on-going clinic trial mix tumor well nhl drug show
monotherapi activ includ object respons tough-to-treat ovarian
cancer given rel clean safeti profil drug believ
deploy compon combin regimen support
notion compani present highli compel data combin
rituximab heavili pretreat nhl patient impress combin
led complet respons patient aggress diffus
larg b-cell lymphoma dlbcl aggress subtyp nhl set
believ efficaci surpass costli difficult-to-toler car-t
product view off-the-shelf combin could offer mani
benefit adopt t-cell therapi without constraint expens
associ autolog car-t could safe deploy patient
poor candid transplant and/or harsh chemotherapi
base view promis earli clinic result forti
seven ascrib valu combin therapi two indic
dlbcl ovarian cancer believ estim leav consider room
upsid compani broad clinic strategi offer multipl shot goal
indic would buyer forti seven share ahead
sever import catalyst expect next month especi
updat clinic data trial nhl ovarian cancer
methodolog summar exhibit model includ contribut
two differ program combin rituximab treatment
r/r dlbcl po regulatori approv commerci launch
combin avelumab treatment ovarian
cancer po regulatori approv commerci launch
believ risk adjust larg line histor data
success rate drug base current stage develop natur
review drug discoveri elect use po
phase dlbcl program due impress earli clinic data
present thu far program includ valuat
elect use discount rate given inher riski drug
develop forti seven lack experi drug commerci
sum-of-the-part valuat two program summar
includ project cash posit per share total npv sum
round
invest thesi depend forti seven abil success develop
manufactur commerci list indic date
test rel small single-arm clinic trial may
predict outcom larger random trial compani may experi
delay complet clinic trial may deal chang
standard care affect develop timelin
forti seven abl success develop commerci may face
price pressur payer forti seven may also face ip-rel risk
novel therapi deem infring issu patent cover compet
product howev believ risk substanti reduc forti
seven recent settlement ip disput synthon biopharmaceut
licens patent form sticht sanquin bloedvoorzien describ
method use therapi oncolog patent
partial overlap forti seven ip see intellectu properti section page
report forti seven enter non-exclus sub-licens
agreement synthon exchang aggreg sum compris
up-front payment futur regulatori commerci mileston
compris signific major aggreg payment
forti seven current reli third-parti manufactur
specif compani secur multi-year contract lonza
believ lonza process antibodi product well valid
suffici scalabl support commercial-scal product howev
acknowledg relianc third-parti could expos forti seven
major development-stag biotechnolog compani abil
maintain suffici fund critic develop progress pipelin
candid current forti seven cash flow neg model
multipl dilut rais may necessari sustain oper
compani potenti achiev sustain profit believ
compani current cash posit sustain oper earli forti
seven went public june current low float may subject forti
seven share increas volatil
pipelin clinic program
nhl includ dlbcl fl
potenti updat data phase trial w/rituximab
potenti initi pivot trial relapsed/refractori nhl w/rituximab
ovarian cancer
potenti phase monotherapi expans cohort result
potenti initi safeti efficaci data phase w/avelumab
indic
potenti genentech initi trial aml bladder
potenti updat result phase trial w/cetuximab
potenti initi data phase aml w/atezolizumab
potenti initi data phase bladder cancer w/atezolizumab
potenti initi data phase aml w/azacitidin
compani present oppenheim co estim
checkpoint modul cpm antibodi
undeni revolution treatment mani cancer central
field immuno-oncolog i/o current repertoir fda-approv
cpm function counteract immunosuppress signal produc cancer
cell therebi releas brake t-cell mediat immun respons
addit inhibitor dozen cpm target
ancillari t-cell checkpoint current clinic develop common
aim improv baselin efficaci wide use drug opdivo
major cpm target t-cell checkpoint logic given t-cell
foot soldier adapt immun system howev see innat
immun system complement adapt immun system target-
rich area i/o drug develop innat adapt immun system
reli differ set cell fulli independ
innat immun respons often critic initi shape adapt
immun respons although cpm focu t-cell checkpoint t-cell
typic constitut rel small fraction immun cell
infiltr tumor contrast innat immun cell macrophag
constitut tumor-infiltr immun cell
due intertwin relationship innat
adapt immun see grow interest innat immun checkpoint target
goal improv overal anti-tumor immun last decad
varieti innat checkpoint includ receptor siglec
identifi potenti therapeut target immunol
cluster differenti
transmembran protein commonli overexpress cancer cell emerg
promis innat target primari focu forti seven therapeut
neg regul macrophag amoeba-lik class innat
immun cell respons engulf digest invad pathogen
cellular debri cancer cell substanc belong healthi
tissu specif serv molecular signal macrophag
instruct refrain phagocytos engulf cell express
marker mechanist checkpoint blockad orthogon
potenti synergist exist checkpoint antibodi forti seven lead
therapeut candid antibodi shown strike
earli clinic proof-of-concept data monotherapi
combin believ could reignit investor interest checkpoint
antibodi space suffer recent high-profil clinic disappoint
target grown increasingli popular believ forti seven
maintain clear clinic develop lead competitor forti seven
gone all-in sole clinical-stag candid current
investig six differ activ clinic trial inhibitor
believ efficaci could span multipl cancer pair nice
oncolog drug view compani impress clinic data
non-hodgkin lymphoma nhl expect multipl clinic readout
next month could substanti de-risk on-going program
varieti solid hematolog cancer
cell innat immun system especi macrophag dendrit cell
nk cell collect outnumb cell adapt immun system
suggest innate-target cpm could provid power new avenu
i/o drug effect anti-tumor immun describ team effort
two arm immun system innat immun cell
first respond tumor peripheri antigen-pres cell includ
dendrit cell macrophag activ travel nearbi lymph node
jump-start anti-tumor t-cell respons immunoth cancer jul
handoff analog relay race initi innat
immun respons pass baton adapt immun system
exhibit innat adapt immun util differ cell
critic checkpoint macrophag function
macrophag antigen present cell play essenti janitori role
bodi remov foreign pathogen infect die dead cancer
cell condit necessari macrophage-medi clearanc
presenc molecular eat signal target cell absenc
inhibitori dont eat molecular signal condit met
macrophag engulf digest prey process call phagocytosi
molecular eat signal found dead distress die cell
typic membrane-bound molecul normal confin
interior cell aberr glycan protein-bas marker calreticulin
 cell physiol apr contrast serv
inhibitori dont eat signal wide express healthi tissu
co-opt tumor cell avoid phagocytosi analog wolf
wear sheep cloth avoid detect
natur bind partner macrophag call signal regulatori
protein sirp interact result signal
cascad disabl phagocytosi block interact
antibodi enabl phagocytosi assum target cell express eat
signal exhibit discuss commonli upregul
tumor overexpress correl poor prognosi see
compel impetu develop therapi target axi
exhibit rational block axi
anti-phagocytot effect first observ context
red blood cell homeostasi specif observ protect
rbc macrophage-medi clearanc scienc rbc
pre-program shed slowli acquir molecular eat
signal age lifespan old cell clear
macrophag maintain homeostasi new product new
protect phagocytosi combin express
lack eat signal
unfortun healthi cell alon express mani tumor
command pathway evad phagocytosi tumor tissu profil
indic express sharpli elev solid liquid
tumor rel normal tissu see exhibit nhl sampl left
tumor type right suggest checkpoint may
commonli exploit cancer
exhibit express select cancer tissu rel normal
cell sep proc natl apr
importantli elev express correl poor prognosi exhibit
highlight outcom two cancer dlbcl ovarian similar
correl observ tumor type includ glioblastoma
cll aml eur cancer
exhibit express prognost outcom
cell sep proc natl apr
target come uniqu
wide express healthi tissu includ red blood cell
identifi therapeut window antibodi come uniqu
challeng howev believ design dose strategi specif
address challeng believ util immunoglobulin subclass
best suit intend use compani implement
proprietari prime dose strategi expand therapeut window allow
satur target cancer cell overcom antigen sink
express healthi tissu believ combin two
factor give forti seven advantag competitor summari
competit landscap refer page report
choic antibodi subclass matter
class monoclon antibodi contain fc domain includ
capac promot cell clearanc mechan independ
block signal specif antibodi fc domain
attract immun cell virtu interact fc domain fc
receptor fcr express immun cell interact promot
antibody-depend cellular phagocytosi adcp antibody-depend
cellular cytotox adcc physiolog adcp adcc import
mechan bodi employ clear extracellular pathogen mani
therapeut antibodi cancer rituximab trastuzumab least
partial reli adcc adcp efficaci name impli adcp end
phagocytosi perform macrophag wherea adcc result
granzyme-medi cell lysi perform nk cell exhibit
exhibit fc region antibodi promot adcc adcp
case target antigen uniqu cancer cell
therefor deploy antibodi could result unwant
adcp/adcc healthi tissu critic question forti seven
address earli develop import adcp/adcc
overal anti-canc activ much activ attribut
phagocytosi answer question forti seven
test sequenc differ immunoglobulin subclass
subclass interact fc receptor differ differ intrins
capac adcp/adcc exampl major differ
subclass antibodi reduc affin certain fc
receptor result impair adcp/adcc rel antibodi
earli vitro experi conduct antibodi suggest
blockad signal adcp/adcc contribut
overal potenc cell sep believ
impli effect therapeut includ fc
domain howev minim risk unwant adcp/adcc healthi
tissu built scaffold forti seven clinic trial
conduct antibodi
see choic scaffold insight prescient decis
separ forti seven competitor exampl safeti
concern surround subclass may contribut trillium
decis pivot system dose use fc
domain intratumor inject trillium develop variant
system dose comprehens review igg subclass
adcc/adcp refer immunol may
although treatment inevit lead anemia on-target/off-tumor
phagocytosi healthi rbc forti seven develop proprietari dose
strategi mitig safeti concern earli develop forti
seven discov initi infus sub-therapeut dose
mg/kg could select elimin oldest circul rbc
accumul eat signal result anemia would like
transient clinic manag new rbc repopul period
sever week exhibit newer rbc lack eat signal
therefor resist phagocytosi allow patient toler
subsequ increas dose see proprietari dose strategi
protect compani ip portfolio key differenti
forti seven competitor importantli believ preced exist
suggest forti seven patent prime dose strategi may defens
natur exampl gilead maintain market exclus angina
product ranexa base ip cover extended-releas format maintain
exhibit purg old red blood cell prime dose
clinic experi
effect monotherapi
believ first antibodi enter clinic
began clinic trial august clinic data present publicli
first time annual meet oral present
primari goal first-in-human trial establish
safeti efficaci clinic valid use compani prime dose
strategi total patient variou solid liquid tumor enrol
note show clear sign activ monotherapi clinic respons
observ patient highli refractori tough-to-treat relapsed/refractori
dlbcl ovarian cancer
patient phase trial enrol three differ cohort
 patient cohort dose singl prime dose
mg/kg mg/kg establish optim prime dose mg/kg
cohort use evalu two differ prime mainten
dose strategi cohort patient receiv singl prime dose follow
weekli mainten dose cohort patient receiv singl
prime dose two load dose weekli mainten dose dose-
limit toxic dlt guid compani select mg/kg prime
establish despit mainten dose test mg/kg
exhibit phase treatment cohort dlt
one concern emerg phase trial observ
hemagglutin clump rbc peripher blood smear sampl
drawn patient howev believ observ lab-
relat artifact involv sampl handl vivo relev safeti
precaut forti seven implement retin scan requir clinic
protocol investig whether hemagglutin could observ patient
safeti databas exceed patient observ
hemagglutin ex vivo correl seriou advers
event clinic believ ex vivo hemagglutin
regard seriou concern patient investor requir
retin scan subsequ remov compani on-going trial
across entir phase experi believ drug demonstr
impress safeti toler summar
exhibit safeti profil phase trial
expect transient anemia common ae incid
grade forti seven implement prime dose appear limit
case grade clinic cours anemia also quit
consist within week prime dose hemoglobin temporarili drop
reticulocyt temporarili increas drop hemoglobin typic resolv
eight week exhibit
exhibit associ transient clinic manag anemia
overcom antigen sink achiev target
phase trial establish recommend phase dose
mg/kg singl infus prime dose follow mg/kg weekli mainten
importantli pharmacokinet pk pharmacodynam pd analys
phase studi confirm dose schedul serum
half-lif day consist commerci viabl biolog
achiev target satur within tumor microenviron
wide express rbc healthi cell must
overcom signific antigen sink effect pk analysi indic
mainten dose least mg/kg abl overcom antigen
sink maintain favor serum half-lif addit concentr
drug plasma exceed threshold identifi preclin model exhibit
shown satur receptor
circul white blood cell wbc penetr deep tissu base
immunohistochem stain axillari lymph node biopsi
exhibit overcom antigen sink dose mg/kg
object respons demonstr monotherapi
colorect breast dlbcl head neck pancreat lung total
phase trial treat patient mainten dose mg/kg
higher two object respons one mix respons
observ intriguingli confirm object respons patient
heavili pretreat line therapi ovarian cancer mix
respons tumor shrinkag recist lesion progress non-
recist lesion occur one two dlbcl patient first-in-
human studi monotherapi cpm view object respons
belong combin therapi
view monotherapi activ favor believ strong
argument exist deploy combin given mild safeti profil
drug illustr could combin target therapeut
antibodi like trastuzumab cetuximab rituximab depend
indic encourag target adcp/adcc along
mediat phagocytosi addit could pair t-cell cpm
exhibit rational deploy combin
believ combin target antibodi rituximab could
highli synergist target agent effect tag cancer cell
addit eat signal block dont eat signal
recal therapeut antibodi contain fc domain engag receptor
macrophag nk cell stimul adcp adcc
interact reduc antibodi illustr
antibodi like rituximab could improv adcp/adcc compon anti-
tumor activ rel monotherapi preclin studi exhibit
confirm synergi target therapi includ
rituximab cetuximab
exhibit potenti synergi rituximab
exhibit combin nhl left right xenograft model
forti seven inc file oral present cri-cimt-eati-aacr
forti seven current evalu clinic safeti efficaci
combin target antibodi nhl antibodi
rituximab colorect cancer anti-egfr antibodi cetuximab
view efficaci combin may depend extent
target antibodi reli adcp/adcc activ
exampl rituximab known stimul adcp wherea cetuximab
target antibodi trastuzumab may heavili reli block
growth signal tumor mab mar-apr
separ forti seven plan investig potenti combin
inhibitor ovarian cancer bladder cancer aml basic
premis combin releas brake innat
adapt arm immun innat immun cell includ
macrophag monocyt dendrit cell also antigen present cell
capabl prime t-cell believ increas phagocytosi could
help initi maintain adapt immun respons cancer cell
support hypothesi shown synerg combin
promot adcp antibodi syngen
exhibit show synergi inhibitor melanoma model
combin show strong efficaci
follow encourag preclin data show synergi
rituximab exhibit forti seven initi phase studi
investig combin therapi patient non-
hodgkin lymphoma nhl includ rel aggress diffus larg b-
cell lymphoma dlbcl indol follicular lymphoma fl
meet forti seven present initi phase result trial
believ strongli support continu clinic develop see
combin potenti altern car-t therapi highli
pretreat patient follow june sec file compani
provid updat clinic outcom eight addit patient
efficacy-evalu patient combin demonstr orr
includ cr rate importantli patient refractori
last rituximab-contain regim suggest addit
make differ median follow-up six month median
durat respons yet reach expect next readout
studi occur like believ data could
major catalyst ftsv share
dcbcl indic believ rituximab combin could provid
chemotherapy-fre option seriou area unmet medic need dlbcl
common type nhl diagnos approxim new
individu year us alon diseas also aggress
patient refractori front-lin secondari treatment
patient overal surviv measur month believ forti seven
could potenti benefit expedit path market strategi
success use now-approv car-t product yescarta kymriah
despit impress efficaci car-t dlbcl
estim major patient would qualifi due
phase data present oral present
forti seven subsequ updat data june sec file
outcom addit five dlbcl patient three fl patient
respons achiev dose cohort mg mainten
dose orr increas dose waterfal plot efficacy-evalu
patient shown
exhibit clinic respons phase trial rituximab
importantli respons seen phase portion studi appear
durabl typic develop within first two month treatment
note respons deepen time exampl one dlbcl patient
improv stabl diseas cr anoth improv pr cr
median follow-up month singl respond patient progress
data cutoff spider plot evalu dlbcl
fl patient shown
exhibit spider plot suggest durabl respons rituximab
importantli combin therapi shown safe appar
overlap toxic anemia remain common seriou grade
advers event view combin safeti profil similar
demonstr monotherapi exhibit
exhibit safeti profil rituximab nhl
sake comparison gilead car-t yescarta achiev
orr cr nhl patient median durat respons
hit month howev sae includ cytokin releas syndrom
neurotox occur patient respect lead
three death addit nearli intent-to-treat patient
popul drop studi due deterior wait
day take manufactur person car-t product
forti seven phase trial began recruit novemb
current enrol patient phase portion forti seven expect enrol
patient trial phase portion trial separ
treatment arm relaps refractori patient fl dlbcl
could provid chemotherapy-fre altern
rituximab first approv becom therapeut mainstay
patient suffer nhl includ dlbcl despit rituximab show littl
efficaci monotherapi rituximab chemotherapi combin highli
activ wide deploy front-lin well salvag set
believ investor compar activ rituximab
combin chemotherapi rituximab combin patient
comparison turn trial retrospect registri
outcom studi conduct support acceler approv
group patient variou categori chemo-refractori
diseas show respons rate salvag therapi larg
similar equal dismal regardless patient treatment histori
present meet rituximab combin
demonstr cr rate treatment-evalu dlbcl patient
believ dlbcl patient refractori recent
rituximab-contain regimen base treatment histori data
discount singl non-refractori patient assum cr rate still
believ phase dataset point substanti improv
cr rate confid interv would
expect rituximab chemo regimen base analysi
exhibit rituximab may less effect
car-t dlbcl believ combin could provid off-the-shelf
chemotherapy-fre could benefit mani patient
exhibit respons rate soc retrospect studi
estim market opportun
previous mention car-t includ kymriah
yescarta approv treatment relapsed/refractori dlbcl per
drug label patient must fail least two prior therapi order qualifi
treatment approv believ rituximab combin would
like compet set car-t highli refractori patient
howev car-t may appropri choic r/r dlbcl patient
leav ampl opportun forti seven gain market share
standard-of-car treatment dlbcl r-chop consist induct
rituximab combin least four monthli cycl chop chemotherapi
cyclophosphamid doxorubicin vincristin prednison major
patient respond well r-chop although approxim
refractori induct addit eventu relaps
patient relaps salvag regimen includ r-ice r-dhap r-
primarili util bridg autolog stem cell transplant auto-
hsct toler use auto-hsct part standard-
of-car second-lin treatment regimen base prima studi
demonstr consolid chemotherapi combin auto-hsct
improv surviv compar consolid therapi alon nej
howev order qualifi auto-hsct patient must
ecog statu either limit transplant approxim
relaps patient order proceed transplant patient must also
demonstr chemosensit salvag regimen
car-t proven effect patient chemorefractori diseas
howev use restrict patient good perform statu
easi treatment toler estim
patient primari refractori relaps follow r-chop induct could
qualifi car-t illustr exhibit estim unmet need
dlbcl highlight patient popul believ rituximab could
exhibit estim address dlbcl patient us
oppenheim co research use estim ann hematol clin oncol sep
market model dlbcl
current ascrib valu rituximab combin
relapsed/refractori dlbcl patient see fl indic less
acut unmet need project potenti fda approv combin
base result random trial compar combin
physician choic salvag regimen patient
relapsed/refractori frontlin r-chop least one addit salvag
regimen howev acknowledg treatment may benefit
acceler path market base single-arm open-label trial use
regulatori strategi adopt car-t
market model estim patient popul
relapsed/refractori dlbcl patient could benefit combin
us eu respect importantli estim nearli
patient would elig car-t
use price estim us eu line
price cpm estim market size approxim
territori combin sale project risk-adjust
assum po given encourag clinic data gener present
thu far assum approv commerci combin
us eu estim peak non-risk-adjust sale
combin market detail market model rituximab combin
dlbcl shown exhibit
exhibit market model combin rituximab dlbcl
diagnos dlbclcases/year elig patients/year cost market size sale forti seven post stanford treat diagnos dlbclcases/year elig patients/year cost market size sale forti seven post royalti stanford penetr treat profit oper expens tax probabl discount dlbcl revenu dlbcl us eu forti seven inc
take solid tumor promis earli
result ovarian cancer
metastat ovarian cancer near uniformli fatal diseas despit
progress made target synthet lethal approach parp
inhibitor overal prognosi patient remain bleak indic
brca wild-typ patient parp inhibitor limit util object
respons particularli difficult achiev patient deem
resist platinum chemotherapi thu encourag data
phase monotherapi trial demonstr two confirm pr patient
cohort heavili pretreat ovarian cancer exhibit
exhibit phase trial monotherapi data ovarian cancer
prior enrol patient progress sever round
chemotherapi top bevacizumab parp inhibitor antibodi
one patient present clear cell ovarian carcinoma show
reduct tumor burden reduct tumor burden accompani
drop protein common biomark ovarian cancer u/ml
baselin u/ml follow-up patient remain treatment
month second patient present fallopian tube cancer
show decreas tumor burden drop u/ml
u/ml remain treatment month
base earli data forti seven expand phase monotherapi
ovarian cancer cohort enrol addit patient expect
data expans cohort could avail view
face extrem low efficaci bar succeed indic exampl
fda recent approv bevacizumab use combin chemotherapi
without show overal surviv benefit howev bevacizumab chemo
combin yield improv vs month orr vs
rel chemotherapi alon
cpm inhibitor gener fail make much
impact ovarian cancer exampl orr studi
pembrolizumab monotherapi previous discuss believ
could display synergi inhibitor could help kick-start
maintain last adapt immun respons test hypothesi forti
seven partner merck kgaa plan investig combin
avelumab antibodi platinum-resist ovarian cancer patient
recent initi trial slate enrol approxim patient
market model ovarian cancer
although yet clinic proof-of-concept data
avelumab combin hand ascrib valu combin
monotherapi ovarian cancer base preclin synergi observ
inhibitor believ fda might
especi accommod novel therapi ovarian cancer given lack
effect option patient fail front-lin chemotherapi surgeri
project fda approv combin base result
random trial compar combin physician choic
salvag regimen platinum-resist patient benchmark market
opportun ovarian cancer base annual number death report
us eu seer eucan statist use price estim
us eu line price
cpm estim market size approxim territori
combin sale project heavili risk-adjust assum
po given earli stage program assum approv
commerci combin us eu
estim peak non-risk-adjust sale combin market
exhibit market model combin avelumab ovarian cancer
case ovarian cancer cost market size sale forti seven post stanford penetr treat case ovarian cancer cost market size sale forti seven post stanford penetr treat profit oper expens tax probabl discount ovarian revenu ovarian cancer us eu annual death ovarian cancer us annual death ovarian cancer eu forti seven inc
addit indic repres upsid
addit nhl ovarian cancer forti seven activ investig plan
investig aml bladder cancer due earli stage
develop elect exclud program estim
howev acknowledg shown sign clinic activ
aml
ovarian cancer particularli difficult cancer treat
metastas object respons exceedingli rare patient fail
front-lin chemotherapi forti seven current enrol
relapsed/refractori patient phase trial
test combin anti-egfr antibodi cetuximab initi
respons rate first patient disclos may sec file
shown two patient achiev partial respons note
patient wild-typ kra statu make difficult deconvolut
activ cetuximab effect kra wild-typ
patient kra mutant expect see addit data trial
believ investor focu whether respons
seen kras-mut patient
exhibit phase combin cetuximab result
chemotherapy-fre regimen aml
forti seven current evalu therapeut potenti aml two
on-going trial plan initi third collabor genentech
patient current treat monotherapi
european camellia trial initi clinic data present
eha confer june importantli dlt observ dose
mg/kg twice weekli view impress aml
often caus anemia underli bone marrow suppress per eha
present anemia attribut monotherapi readili
manag transfus view safe use aml suggest
drug toler wide rang cancer patient
term efficaci two efficacy-evalu patient show evid
biolog activ reduct bone marrow blast
reduc bone marrow cellular specul patient qualifi
pr classif due incomplet recoveri peripher blood
count addit one patient demonstr mark increas bone marrow
infiltr t-cell follow therapi observ influx t-cell may partial
explain compani plan initi separ trial aml investig
combin atezolizumab collabor genentech slate
initi separ forti seven initi trial
pair hypomethyl agent azacitidin use
relapsed/refractori aml patient inelig treatment
standard cytarabin anthracyclin induct chemotherapi trial also
enrol intermediate- high- high-risk r/r treatment-nav
forti seven sole clinic stage therapeut candid
compani pipelin includ anti-sirp antibodi
preclin develop solid tumor per compani file
could enter clinic compani also develop pro-phagocytot
antibodi target ckit antigen express numer cancer includ
leukemia melanoma gastrointestin stroma tumor gist
first antibodi enter clinic first patient
dose august last four year sever compet compani
initi clinic trial drug target axi view
least year head start next closest competitor celgen cc-
also antibodi see exhibit
clinical-stag competitor target base
scaffold altern trillium alexo develop product base
sirp protein fuse antibodi fc domain serv decoy receptor
prevent signal note use decoy receptor could
sidestep problem on-target off-tumor activ
trillium util fc domain molecul demonstr
compel sign activ dlbcl monotherapi combin
rituximab meet howev believ high-grad case
thrombocytopenia may forc compani alter dose strategi
system intralesion inject compani refocus
near-term effort patient cutan t-cell lymphoma peripher t-
cell lymphoma note trillium sirp fusion slate
enter clinic note sever forti seven competitor
includ surfac celgen point hemagglutin possibl
area concern tout data healthi donor blood show
compet product lead ex vivo hemagglutin question
relev data ex vivo hemagglutin observ
treat blood sampl appear clinic repercuss
forti seven accumul larger safeti databas
exhibit competit landscap drug target axi
forti seven core ip portfolio licens stanford univers
includ issu patent approxim pend patent applic
march patent subject retain right stanford
allow academ non-profit research institut practic licens
technolog patent non-commerci purpos believ
non-exclus licens relat use therapeut
protect composition-of-matt methods-of-us patent forti
seven also patent proprietari dose strategi compani ip
portfolio includ us patent relat product includ
expect expir exclud possibl
extens patent term addit compani ip portfolio includ
sever patent patent applic relat anti-sirp product
candid potenti applic non-oncolog indic
key patent famili describ blockad pathway
treat cancer us prioriti date januari
second famili us cover method treat blood cancer
forti sevencelgenealexoarch oncologysurfac prematur tumor includ colorect ovarian bladder cancer liquid tumor includ aml dlbcl solid tumour incluidng small cell lung cancer germ cell neuroblastoma liquid tumor includ multipl myeloma nhl aml mdscutan t-cell lymphoma peripher t-cell lymphoma liquid tumor includ nhl multipl myelomasolid liquid tumor includ nhlsbenign malign neoplasm includ cyst polypsadvanc solid cancer hematolog cancersb-cel leukemia lymphoma includ ftsv outperform
combin antibodi prioriti date
septemb third famili us cover sub-therapeut
prime dose strategi prioriti date march
recent forti seven stanford engag ip disput
synthon biopharmaceut disput center us
relat european patent ep describ use anti-
antibodi anti-sirp antibodi combin certain
antibodi includ rituximab cetuximab treatment cancer
patent prioriti date april overlap stanford ip
juli forti seven sign settlement licens agreement
synthon synthon agre grant non-exclus world-wide
sublicens relev ip believ prevent patent litigation-
relat delay clinic develop futur commerci
exchang sublicens forti seven agre pay synthon
aggreg includ up-front payment regulatori
commerci mileston compris signific major aggreg
fee per agreement forti seven requir pay synthon annual
licens fee tier low single-digit royalti futur sale
forti seven approxim million cash cash equival
market secur end compani went public june
rais gross proce least overallot option
rais addit believ compani pro forma cash
posit exclud exercis overallot option could
sustain oper earli includ three dilut rais
model total could sustain compani profit
growth
project loss
per share respect expect see increas cash burn
associ increas sg advanc clinic
believ combin rituximab use dlbcl could
approv commerci us eu project peak non-
risk-adjust sale believ combin avelumab
use ovarian cancer could approv commerci us eu
project peak non-risk-adjust sale
introduc estim increas
introduc estim increas
assum cog believ line
approv monoclon antibodi assum compani could requir
sale forc approxim rep success market us
presid chief execut offic
presid ceo
mccamish presid ceo forti seven intern expert
biosimilar biolog mccamish passion mentor
develop peopl focus meet patient need effici
commerci viabl effort senior execut extens experi
multipl compani includ protein design lab abbott novartis-
sandoz led pioneer effort file launch biosimilar world-wide
demonstr commerci mindset establish research
develop strategi lead approv commerci success multipl
therapeut area regulatori categori includ biolog biosimilar
drug devic medic food held professorship univers
california davi ohio state univers complet phd
nutrit scienc state md ucla complet
resid fellowship train uc davi mccamish receiv bachelor
master degre uc santa barbara
takimoto year experi clinic oncolog develop
chief medic offic forti seven prior forti seven held variou
posit johnson johnson ultim becom vice presid
experiment medicin earli develop oncolog janssen
becam associ professor univers texa scienc center
san antonio uthscsa subsequ held zachri chair
translat research institut drug development/canc therapi
research center also professor adjunct pharmacolog
uthscsa help found independ phase oncolog
start san antonio princip co-investig
earli phase oncolog clinic trial prior start takimoto serv senior
investig nation cancer institut nci medicin branch
also complet fellowship medic oncolog nci clinic
pharmacolog uniform servic univers receiv md
yale univers phd pharmacolog yale univers bachelor
degre chemistri stanford univers publish
research articl review editori book chapter serv
editori board numer oncolog public
rhoad spent year life scienc industri serv
chief offic forti seven previous serv execut vice
presid cfo treasur secretari role oversaw
area financi manag rais approxim
initi public offer subsequ public equiti debt
financ facilit in-licens lead product candid
prior join rhoad cfo premier
execut long-term strateg plan result revenu growth
led acquisit two compani earlier work
vice presid sprout group ventur capit affili lufkin
jenrett consult bain compani member leverag
buy-out princip invest group merril lynch rhoad hold mba
harvard busi school bs busi administr
concentr financ univers arkansa
gibb spent year biopharmaceut industri includ year
genentech gilead varieti research busi role serv
chief busi offic forti seven passion translat
scientif innov benefit patient also serv board
director previous board director
chairman scientif advisori board tobira therapeut
acquir allergan prior gibb spent year gilead leadership
role includ vice presid commerci strategy/plan oper
senior director corpor develop senior director biolog research
contribut develop launch fda-approv drug
prior gilead spent three year protein engin depart
genentech visit post-doctor scientist gibb publish
scientif articl inventor three issu patent receiv phd
molecular biolog univers glasgow scotland bs hon
biochemistri massey univers new zealand golden
gate univers san francisco
kruse year experi patent attorney
biotechnolog industri prior join forti seven vice presid
intellectu properti chief patent counsel verinata health
verinata acquisit senior director intellectu properti
prior kruse vice presid intellectu properti chief
patent counsel maxygen year maxygen develop
defend enforc industry-lead patent portfolio direct molecular
evolut rank mit technolog review patent scorecard
biotechnolog patent estat patent portfolio also form basi
sever success compani spun sold maxygen includ
ipo verdia acquir dupont avidia acquir
prior maxygen kruse patent attorney chiron corpor
respons chiron gene therapi patent portfolio began legal
career attorney townsend townsend crew work
biotechnolog patent prosecut strategi hold phd biochemistri
univers washington jd golden gate univers school
law san francisco receiv bs biochemistri uc davi
sec file oppenheim co research
figur thousand except per share expens good sold research develop gener administr oper loss incom loss incom incom tax benefit incom loss per share share outstand comark breidenbach forti seven inc
sec file oppenheim co research
figur thousand except per share cash short-term prepaid expens current current properti equip account accru defer grant fund current lease-rel liabil long-term convert prefer addit paid-in comprehens stockhold liabil stockhold comark breidenbach ftsv outperform
stock price compani mention report close
